Litigation Details for IN RE: Entresto (Sacubitril/Valsartan) Patent Litigation (J.P.M.L. 2019)

IN RE: Entresto (Sacubitril/Valsartan) Patent Litigation (J.P.M.L. 2019)

Docket		Date Filed	2019-12-19
Court	United States Judicial Panel on Multidistrict Litigation	Date Terminated
Cause		Assigned To	Leonard P. Stark
Jury Demand		Referred To
Patents	8,101,659; 8,796,331; 8,877,938; 9,388,134
Link to Docket	External link to docket

Details for IN RE: Entresto (Sacubitril/Valsartan) Patent Litigation (J.P.M.L. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-12-19	1	Memorandum	where a patent 4 Plaintiff has asserted U.S. Patent Nos. 8,877,938 and 9,388,134 (“’938 patent” and …and “’134 patent,” respectively) against all defendants. Plaintiff also has asserted U.S. Patent No. 8,101,659…8,101,659 (“’659 patent”) against all defendants except Alembic, Lupin, and Noratech and U.S. Patent No. 8,796,331…’331 patent”) against all Defendants except Alembic, Lupin, Macleods, and Noratech. These patents are …underlying the patents, prior art, claim construction and issues of infringement involving the patents.” In re	External link to document
2020-03-27	78		The patents are U.S. Patents Nos. 8,101,659 (the ’659 patent), 8,796,331 (the ’331 patent), 8,877,…8,877,938 (the ’938 patent), and 9,388,134 (the ’134 patent). Plaintiff alleges that all defendants in all… and ’134 patents, and that most of the defendants also infringed the ’659 and ’331 patents. … MDL No. 2930 PATENT LITIGATION …actions on the motion are a series of Hatch-Waxman3 patent infringement lawsuits, in which Novartis alleges	External link to document